Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: To reveal the potential mechanism of PDA on hepatocellular carcinoma SMMC-7721 cells in vitro.

Methods: The cytotoxic activity, colony formation, cell cycle distribution, apoptosis and their associated protein analysis, intracellular reactive oxygen species (ROS) and Ca levels, proteins in Nrf2 and Ntoch pathways and metabolite profiles of PDA against hepatocellular carcinoma were investigated.

Results: PDA with cytotoxic activity inhibited cell proliferation and migration, increased intracellular ROS, Ca levels and MCUR1 protein expression in a dose-dependent manner, caused cell cycle arrest in the S phase and induced apoptosis via adjusting the levels of Bcl-2, Bax, and Caspase 3 proteins, and inhibited the activation of Notch1, Jagged, Hes1, Nrf2 and HO-1 proteins. Metabonomics data showed that PDA significantly regulated 144 metabolite levels tend to be normal level, especially carnitine derivatives, bile acid metabolites associated with hepatocellular carcinoma, and mainly enriched in ABC transporter, arginine and proline metabolism, primary bile acid biosynthesis, Notch signaling pathway, etc, and proved that PDA markedly adjusted Notch signaling pathway.

Conclusion: PDA exhibited the proliferation inhibition of SMMC-7721 cells by inhibiting ROS/Nrf2/Notch signaling pathway and significantly affected the metabolic profile, suggesting PDA could be a potential therapeutic agent for patients with hepatocellular carcinoma.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290457PMC
http://dx.doi.org/10.2147/JHC.S403630DOI Listing

Publication Analysis

Top Keywords

hepatocellular carcinoma
20
metabolite profiles
8
pda hepatocellular
8
smmc-7721 cells
8
cytotoxic activity
8
cell cycle
8
ros levels
8
bile acid
8
notch signaling
8
signaling pathway
8

Similar Publications

Purpose: To evaluate the feasibility of abbreviated liver magnetic resonance imaging (AMRI) with a second-shot arterial phase (SSAP) image for the viability of treated hepatocellular carcinoma (HCC) after non-radiation locoregional therapy (LRT).

Methods: We retrospectively enrolled patients with non-radiation LRT for HCC who underwent the modified gadoxetic acid-enhanced liver MRI protocol, which includes routine dynamic and SSAP imaging after the first and second injection of gadoxetic acid, respectively (6 mL and 4 mL, respectively), and an available reference standard for tumor viability in the treated HCC between March 2021 and February 2022. Two radiologists independently reviewed the full-protocol MRI (FP-MRI) and AMRI with SSAP.

View Article and Find Full Text PDF

Purpose: Targeted therapy with lenvatinib is a preferred option for advanced hepatocellular carcinoma, however, predicting its efficacy remains challenging. This study aimed to build a nomogram integrating clinicoradiological indicators and radiomics features to predict the response to lenvatinib in patients with hepatocellular carcinoma.

Methods: This study included 211 patients with hepatocellular carcinoma from two centers, who were allocated into the training (107 patients), internal test (46 patients) and external test set(58 patients).

View Article and Find Full Text PDF

Agranulocytosis is an extremely rare but potentially fatal immune-related adverse event (irAE) induced by immune checkpoint inhibitors (ICIs). Its management, particularly following combination therapies such as durvalumab/tremelimumab (Dur/Tre) for hepatocellular carcinoma (HCC), is challenging owing to limited data. We herein report a 79-year-old man with HCC who developed severe Dur/Tre-induced agranulocytosis that was refractory to granulocyte colony-stimulating factor, high-dose corticosteroids, and intravenous immunoglobulin.

View Article and Find Full Text PDF